GSK and Merck Group-backed Progyny floated in an offering that involved the fertility benefits manager pricing its shares below their range.

Progyny, a US-based fertility benefits platform backed by pharmaceutical firms GlaxoSmithKline (GSK) and Merck Group, went public on Friday in a $130m initial public offering. The company issued 6.7 million of new shares on the Nasdaq Global Select Market priced at $13 each while existing backers including Merck sold a combined 3.3 million shares. It…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.